Justin Stebbing

Justin Stebbing

Imperial College London

H-index: 88

Europe-United Kingdom

About Justin Stebbing

Justin Stebbing, With an exceptional h-index of 88 and a recent h-index of 57 (since 2020), a distinguished researcher at Imperial College London, specializes in the field of cancer.

His recent articles reflect a diverse array of research interests and contributions to the field:

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

Genes and Race in Colon Cancer

Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma

LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC).

An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS

Justin Stebbing Information

University

Position

___

Citations(all)

32417

Citations(since 2020)

17273

Cited By

22205

hIndex(all)

88

hIndex(since 2020)

57

i10Index(all)

395

i10Index(since 2020)

223

Email

University Profile Page

Google Scholar

Justin Stebbing Skills & Research Interests

cancer

Top articles of Justin Stebbing

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

Nature Communications

2024/2/6

Genes and Race in Colon Cancer

2024/2/1

Justin Stebbing
Justin Stebbing

H-Index: 51

Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma

Molecular biotechnology

2024/2

An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma

BMC Medical Genomics

2024

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study

Breast Cancer Research and Treatment

2024/4/6

Qi Guo
Qi Guo

H-Index: 10

Justin Stebbing
Justin Stebbing

H-Index: 51

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

JCO Precision Oncology

2024/4

The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS

Respiratory Research

2024/4/1

Justin Stebbing
Justin Stebbing

H-Index: 51

Sotirios Tsiodras
Sotirios Tsiodras

H-Index: 35

Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer

Clinical Cancer Research

2024/3/28

Justin Stebbing
Justin Stebbing

H-Index: 51

Kinome‐Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma

Advanced Science

2024/2/14

A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease

Experimental hematology & oncology

2023/12/1

A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing data

Heliyon

2023/11/1

The mutational landscape of the adult healthy parous and nulliparous human breast

Nature Communications

2023/9/6

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

2023/8/18

Patrizia Diana
Patrizia Diana

H-Index: 27

Justin Stebbing
Justin Stebbing

H-Index: 51

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 …

BioDrugs

2023/5

Kinome-wide synthetic lethal screen identifies PANK4 as modulator of resistance in glioblastoma

2023/3/27

Comparison of phenomics and cfDNA in a large breast screening population: The Breast Screening and Monitoring Study (BSMS)

Oncogene

2023/1/24

A pyroptosis‐related lncRNA signature in bladder cancer

Cancer medicine

2023/3

Design and reporting of phase III oncology trials with prospective biomarker validation

JNCI: Journal of the National Cancer Institute

2023/2/1

The inhibitory properties of a novel, selective LMTK3 kinase inhibitor

International Journal of Molecular Sciences

2023/1/3

See List of Professors in Justin Stebbing University(Imperial College London)